TORQUE’S GLIMTOR MV2

Torque’s Glimtor MV2 Tablets contains Glimepiride, a sulphonylurea antihyperglycaemic agent acts mainly by stimulating insulin release from pancreatic beta cells, Metformin, a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose and Voglibose, an alpha glucosidase inhibitor.

Categories: ,

Product Description

Description: Torque’s Glimtor MV2 Tablets contains Glimepiride, a sulphonylurea antihyperglycaemic agent acts mainly by stimulating insulin release from pancreatic beta cells, Metformin, a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose and Voglibose, an alpha glucosidase inhibitor.

Pharmaceutical Dosage Form: Tablet

Route of Administration: Oral

Composition: Each uncoated bilayered tablet contains:

Glimepride IP                                             1 mg

Metformin Hydrochloride IP                        500 mg

(As extended release)

Voglibose IP                                               0.2 mg

Excipients                                                   q.s.

Mechanism of Action: Glimepiride primarily lowers blood glucose by stimulating the release of insulin from pancreatic beta-cells. It binds to the sulphonylurea receptor in the pancreatic beta-cell plasma membrane, leading to closure of the ATP-sensitive potassium channel, thereby stimulating the release of insulin. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Voglibose is an alpha glucosidase inhibitor which reduces intestinal absorption of starch, dextrin, and disaccharides by inhibiting the action of α-glucosidase in the intestinal brush border. Inhibition of this enzyme catalyzes the decomposition of disaccharides into monosaccharides and slows the digestion and absorption of carbohydrates; the postprandial rise in plasma glucose is blunted in both normal and diabetic subjects resulting in improvement of post prandial hyperglycemia and various disorders caused by hyperglycemia.

Indications: Torque’s Glimtor MV2 is indicated for the treatment of patients with type II diabetes mellitus when diet, exercise and single agent does not result in adequate glycemic control.

Dosage: As directed by the physician.

Storage: Store at a temperature not exceeding 30ºC, protect from light & moisture.

Presentation: 10 x 15

Side effects: The following adverse reactions may occur:

Lactic Acidosis

Taste Disturbance

Nausea, Vomiting, Diarrhoea, Abdominal Pain, Flatulence, Loss of Appetite

Upper respiratory tract infection

Anaemia

Hypo-Glycaemia

Hypo-Aesthesia

Headache, Dizziness

Arthralgia, Back Pain

Haematuria

Erectile Dysfunction

Contraindications:

Torque’s Glimtor MV2 is contraindicated in patients with:

Known hypersensitivity to metformin, glimepiride, voglibose or any of the components of this product.

Severe renal impairment

Acute or chronic metabolic acidosis, including diabetic ketoacidosis and lactic acidosis

Diabetic pre-coma

Patients with established NYHA class III or IV heart failure

Acute or chronic disease which may cause tissue hypoxia such as cardiac or respiratory

failure, recent myocardial infarction, shock

Hepatic insufficiency, acute alcohol intoxication, alcoholism

Acute conditions with the potential to alter renal function such as:

– Dehydration

– Severe infection

– Shock

– Intravascular administration of iodinated contrast agents

Lactation

Drug Interactions:

Alcohol

NSAIDs

ACE Inhibitors

Angiotensin II Receptor Antagonists

Diuretics

Verapamil

Rifampicin

Cimetidine, Dolutegravir, Ranolazine, Trimethoprime,

Isavuconazole, Fluconazole

Vandetanib, Crizotinib, Olaparib

Thyroid Stimulating Agents, Glucocorticoids

Anabolic Steroids and Male Sex Hormones

Gemfibrozil